Search Results
69 results
Your search is now limited to «Prostate Cancer» expert search.
Your search is now limited to only one Source. To return to results from all sources click here. 02/14/2019 16:44
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced data evaluating Opdivo (nivolumab) in combination with Yervoy (ipilimumab) in patients with metastatic castration-resistant prostate cancer (mCRPC). Results from an interim analysis of the Phase 2 CheckMate -650 trial showed that among 32 asymptomatic or minimally symptomatic patients whose disease had progressed after second-generation hormone therapy and who had not received chemotherapy (cohort 1), with a median follow-up of 11.9 months, the objective response rate (ORR) was 25%. Additionally, among 30 patients whose disease progressed after taxane-based chemotherapy (cohort 2), with a median... 02/14/2019 09:40
Media Inquiries: Brian Kenney Phone: 215-628-7010 Suzanne Frost Phone: 416-317-0304 Investor Relations: Christopher DelOrefice Phone: 1-732-524-2955 Lesley Fishman Phone: 1-732-524-3922 U.S. Medical Inquiries: 1-800-526-7736 Janssen Announces Preliminary Results from Phase 2 GALAHAD Study in Adults with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Pathway Defects (DRD) Data showed niraparib demonstrated an objective response rate of approximately 40 percent in patients with metastatic castration-resistant prostate cancer and DNA-repair pathway defects, specifically BRCA1/2 SAN FRANCISCO, February 14, 2019 - The Janssen Pharmaceutical Companies of Johnson & Johnson will... 02/14/2019 07:43
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of interim data from the Phase 1b/2 KEYNOTE-365 umbrella trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, in combination with various agents for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). 02/11/2019 17:41
Data to be presented at the 2019 Genitourinary Cancers Symposium NEW YORK & TOKYO--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., 'Astellas') announced today results from the Phase 3 ARCHES trial in men with metastatic hormone-sensitive prostate cancer (mHSPC). 02/08/2019 23:08
Dear Dr. Roach: After blood analysis revealed elevated PSA levels, a urologist felt a lump on my prostate and arranged a biopsy. Of 12 samples taken, three were cancerous. The doctor recommends removal instead of radiation or any other therapy. I asked which type of cancer it is, and he replied that it is just cancer and won't spread in a month or two but I should not wait too long to have the surgery.I am concerned about negative physical consequences, but realize whatever they are ...... 02/08/2019 12:49
WASHINGTON (February 8, 2019) - A large national study examining a radiation treatment for prostate cancer - popular because it delivers a high dose of therapy in a very short time frame - supports its routine use. The study, conducted at cancer centers around the country including at Georgetown Lombardi Comprehensive Cancer Center, looks at long-term follow-up data for stereotactic body radiotherapy (SBRT) used to treat more than 2,100 men with prostate cancer that had a low or intermediate risk of recurring. The results were published Feb. 8 in the journal JAMA Network Open. At Georgetown, the therapy is delivered by a system called the CyberKnife,... 02/05/2019 08:33
2/5/2019 Orion Corporation Press Release 5 February 2019 at 3.00 p.m. EET Orion and Bayer jointly present new data in prostate cancer from the Darolutamide ARAMIS -study First presentation of data from the pivotal Phase III ARAMIS trial with the investigational compound darolutamide in patients with advanced prostate cancer that has not yet metastasized will be presented at 2019 ASCO GU Cancers Symposium. Orion Corporation and Bayer announced today that research on their jointly developed investigational compound darolutamide will be presented at the 2019 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium taking place February 14-16 in San Francisco. Among the...

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications